UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F

(Mark One)

o	REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
x	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020
OR
o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
o	SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report…………………………………..

For the transition period from                     to                   

Commission file number: 001-11960

ASTRAZENECA PLC

(Exact name of Registrant as specified in its charter)

England and Wales

(Jurisdiction of incorporation or organization)

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

England

(Address of principal executive offices)

Adrian Kemp

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

England

Telephone: +44 20 3749 5000

Facsimile number: +44 1223 352 858

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing one half of an Ordinary Share of 25¢ each	AZN	The Nasdaq Stock Market LLC
Ordinary Shares of 25¢ each		The Nasdaq Stock Market LLC *
2.375% Notes due 2022	AZN 22A	The Nasdaq Stock Market LLC
Floating Rate Notes due 2022	AZN 22B	The Nasdaq Stock Market LLC
3.500% Notes due 2023	AZN 23	The Nasdaq Stock Market LLC
7.000% Notes due 2023	AZN / 23	The Nasdaq Stock Market LLC
Floating Rate Notes due 2023	AZN 23A	The Nasdaq Stock Market LLC
3.375% Notes due 2025	AZN 25	The Nasdaq Stock Market LLC
0.700% Notes due 2026	AZN 26	The Nasdaq Stock Market LLC
3.125% Notes due 2027	AZN 27A	The Nasdaq Stock Market LLC
4.000% Notes due 2029	AZN 29	The Nasdaq Stock Market LLC
1.375% Notes due 2030	AZN 30	The Nasdaq Stock Market LLC
6.450% Notes due 2037	AZN 37	The Nasdaq Stock Market LLC
4.000% Notes due 2042	AZN 42	The Nasdaq Stock Market LLC
4.375% Notes due 2045	AZN 45	The Nasdaq Stock Market LLC
4.375% Notes due 2048	AZN 48	The Nasdaq Stock Market LLC
2.125% Notes due 2050	AZN 50	The Nasdaq Stock Market LLC

*       Not for trading, but only in connection with the registration of American Depositary Shares representing such Ordinary Shares pursuant to the requirements of the Securities and Exchange Commission.

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None

(Title of Class)

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

The number of outstanding shares of each class of stock of AstraZeneca PLC as of December 31, 2020 was:

Title of Class	Number of Shares Outstanding
Ordinary Shares of 25¢ each:	1,312,668,724
Redeemable Preference Shares of £1 each:	50,000

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes x  No o

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes o  No x

Note — Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x  No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x  No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer x	Accelerated Filer o	Non-accelerated Filer o
		Emerging growth company o

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. o

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. x

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP o International Financial Reporting Standards as issued by the International Accounting Standards Board x Other o

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

o Item 17  o Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o  No x

(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

Yes o  No o

Pursuant to Rule 12b-23(a) of the Securities Exchange Act of 1934, as amended, the information for the 2020 Form 20-F of AstraZeneca PLC (the “Company”) set out below is being incorporated by reference from AstraZeneca’s “Annual Report and Form 20-F Information 2020” included as exhibit 15.1 to this Form 20-F dated and submitted on February 16, 2021.

References below to major headings include all information under such major headings, including subheadings, unless such reference is a reference to a subheading, in which case such reference includes only the information contained under such subheading. Unless the context otherwise requires, “AstraZeneca” or “Group” refers to the Company and its consolidated entities. Other information contained within AstraZeneca’s “Annual Report and Form 20-F Information 2020” included as exhibit 15.1 to this Form 20-F, including graphs and tabular data, is not included in this Form 20-F unless specifically identified below. Photographs are also not included.

In addition to the information set out below, the information (including tabular data) set forth under the headings “Use of terms” on the inside front cover, “Strategic Report—Financial Review—Measuring performance” on page 84, and the tables on page 85, “Additional Information —Trade Marks” on page 279, “—Glossary” on pages 280 to 283 and “—Important information for readers of this Annual Report—Cautionary statement regarding forward-looking statements”, “—Inclusion of Reported performance, Core financial measures and constant exchange rate growth rates”, “—Statements of competitive position, growth rates and sales”, “— AstraZeneca websites”, “—External/third-party websites” and “—Figures” on page 284, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2020” included as exhibit 15.1 to this Form 20-F dated February 16, 2021 is incorporated by reference. References herein to AstraZeneca websites, including where a link is provided, are textual references only and information on or accessible through such websites does not form part of and is not incorporated into this Form 20-F dated February 16, 2021. Reference to “audited” information (including graphs and tabular data) set forth under the heading “Corporate Governance—Directors’ Remuneration Report” refers to procedures performed by the Company’s external auditor in accordance with International Standards on Auditing (UK) (‘ISAs (UK)’) and applicable law and does not form part of the “Report of Independent Registered Public Accounting Firm” in Item 18 herein.

PART 1

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Not applicable.

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

ITEM 3. KEY INFORMATION

A.        Selected Financial Data

The information (including graphs and tabular data) set forth under the headings “Financial Statements—Group Financial Record” on page 243, “Additional Information—Shareholder Information—Issued share capital, shareholdings and share prices” and the first table that appears under “—Ordinary Shares in issue” on page 269, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2020” included as exhibit 15.1 to this Form 20-F dated February 16, 2021 is incorporated by reference. The selected financial data incorporated by reference herein is derived from audited financial statements of the Company and its consolidated entities included in AstraZeneca’s “Annual Report and Form 20-F Information 2020” included as exhibit 15.1 to this Form 20-F dated February 16, 2021. The audited financial statements of the Company and its consolidated entities have been prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 and International Financial Reporting Standards (“IFRSs”) adopted pursuant to Regulation (EC) No 1606/2002 as it applies in the European Union. The audited financial statements of the Company and its consolidated entities also comply fully with IFRSs as issued by the International Accounting Standards Board (“IASB”).

B.        Capitalization and Indebtedness

Not applicable.

C.        Reason for the Offer and Use of Proceeds

Not applicable.

D.        Risk Factors

The information (including tabular data) set forth or referenced under the heading “Additional Information—Risk” on pages 254 to 266 of AstraZeneca’s “Annual Report and Form 20-F Information 2020” included as exhibit 15.1 to this Form 20-F dated February 16, 2021 is incorporated by reference.

2

ITEM 4. INFORMATION ON THE COMPANY

A.        History and Development of the Company

The information (including tabular data) set forth under the headings “Additional Information—Shareholder Information—History and development of the Company” on page 268, “Strategic Report—Financial Review— Collaboration Revenue” on page 88, “Strategic Report—Financial Review—Financial position - 31 December 2020—Business combinations” on page 92, “Strategic Report—Financial Review—Financial Position – 31 December 2020—Investments, divestments and capital expenditure” on page 94, “Corporate Governance—Corporate Governance Report—Compliance with the UK Corporate Governance Code—Board Leadership and Company Purpose” on page 114 and “Additional Information—Important information for readers of this Annual Report— AstraZeneca websites” on page 284, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2020” included as exhibit 15.1 to this Form 20-F dated February 16, 2021 is incorporated by reference.

The United States Securities and Exchange Commission (the “SEC”) maintains a website at www.sec.gov which contains in electronic form each of the reports and other information that we have filed electronically with the SEC.

B.        Business Overview

The information (including graphs and tabular data) set forth under the headings “Strategic Report—AstraZeneca at a glance” on pages 2 to 3, “Strategic Report—Chairman’s Statement” on page 4, “Strategic Report—Chief Executive Officer’s Review” on pages 5 to 6, “Strategic Report—Our Strategy and Key Performance Indicators” on pages 18 to 22, “Strategic Report—Performance in 2020” on pages 24 to 29; “Strategic Report—Performance in 2020—COVID-19 pandemic” on pages 28 and 29; “Strategic Report—Therapy Area Review” on pages 30 to 51, “Strategic Report—Business Review” on page 52 to 77, “Strategic Report— Risk Overview—Managing risk”, “—Risk Overview— Emerging risks”, “—Risk Overview—Climate risk”, “—Risk Overview—Risk management embedded in business processes” on page 78, “Strategic Report—Risk Overview—Brexit”, “—Risk Overview—COVID-19 pandemic” on page 79, “Corporate Governance—Corporate Governance Report—Other Governance information—Risk management and controls—Global Compliance and Internal Audit Services (IA)” on page 118, “Additional Information— Development Pipeline as at 11 February 2021” on pages 245 to 250, “Additional Information—Patent Expiries of Key Marketed Products” on pages 251 to 253, “Additional Information—Sustainability: supplementary information” on page 275, “Financial Statements—Notes to the Group Financial Statements—Note 1—Revenue” on pages 187 to 188, “Financial Statements—Notes to the Group Financial Statements—Note 6—Segment information” on pages 193 to 194, and “Additional Information—Important information for readers of this Annual Report—Statements of competitive position, growth rates and sales” on page 284, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2020” included as exhibit 15.1 to this Form 20-F dated February 16, 2021 is incorporated by reference.

Geographical Review

This section Item 4—“Information on the Company— Business Overview—Geographical Review” should be read in conjunction with Item 5—“Operating and Financial Review and Prospects—Operating Results” below.

	World					Emerging Markets					U.S.			Europe					Established ROW
2020	Sales $m	Actual %		CER %		Sales $m	Actual %		CER %		Sales $m	Actual %		Sales $m	Actual %		CER %		Sales $m	Actual %		CER %
Oncology:
Tagrisso	4,328	36		36		1,208	59		63		1,566	24		748	58		56		806	18		16
Imfinzi	2,042	39		39		158	n/m		n/m		1,185	14		370	n/m		n/m		329	51		49
Lynparza	1,776	48		49		264	98		n/m		876	40		435	52		51		201	32		32
Calquence	522	n/m		n/m		6	n/m		n/m		511	n/m		2	n/m		n/m		3	n/m		n/m
Koselugo	38	n/m		n/m		n/m	n/m		n/m		38	n/m		—	n/m		n/m		n/m	n/m		n/m
Zoladex	888	9		13		561	14		20		5	(22	)	140	4		4		182	1		1
Faslodex	580	(35	)	(34	)	180	(9	)	(4	)	55	(83	)	221	(3	)	(3	)	124	(10	)	(11	)
Iressa	268	(37	)	(36	)	221	(23	)	(22	)	14	(21	)	12	(82	)	(82	)	21	(57	)	(57	)
Arimidex	185	(18	)	(16	)	147	(3	)	1		n/m	n/m		3	(88	)	(88	)	35	(23	)	(24	)
Casodex	172	(14	)	(14	)	133	4		6		n/m	n/m		3	(83	)	(83	)	36	(37	)	(38	)
Others	51	(47	)	(46	)	28	(1	)	1		n/m	n/m		4	(41	)	(40	)	19	(69	)	(69	)
Total Oncology	10,850	25		26		2,906	31		36		4,250	23		1,938	36		35		1,756	11		10
CVRM:
Farxiga	1,959	27		30		686	46		55		569	6		507	36		35		197	21		21
Brilinta	1,593	1		2		461	—		4		732	3		342	(3	)	(3	)	58	n/m		2
Onglyza	470	(11	)	(10	)	201	14		18		166	(28	)	58	(16	)	(17	)	45	(12	)	(11	)
Bydureon	448	(18	)	(18	)	4	(62	)	(59	)	382	(17	)	53	(20	)	(20	)	9	(32	)	(31	)
Byetta	68	(37	)	(36	)	8	(35	)	(23	)	37	(45	)	14	(24	)	(24	)	9	(18	)	(17	)
Other diabetes	47	(10	)	(10	)	7	n/m		n/m		25	(37	)	13	38		38		2	26		28
Lokelma	76	n/m		n/m		5	n/m		n/m		57	n/m		4	n/m		n/m		10	n/m		n/m
Crestor	1,180	(8	)	(7	)	748	(7	)	(5	)	92	(11	)	129	(13	)	(15	)	211	(4	)	(5	)
Seloken/Toprol-XL	821	8		12		782	14		18		13	(66	)	16	(35	)	(35	)	10	(11	)	(10	)
Atacand	243	10		15		175	9		17		10	(12	)	35	17		17		23	15		15
Others	191	(30	)	(30	)	126	(35	)	(34	)	n/m	n/m		57	(5	)	(4	)	8	(60	)	(61	)
Total CVRM	7,096	3		5		3,203	8		12		2,083	(6	)	1,228	7		6		582	2		2
Respiratory & Immunology:
Symbicort	2,721	9		10		567	4		9		1,022	23		694	2		2		438	(1	)	—
Pulmicort	996	(32	)	(32	)	798	(33	)	(33	)	71	(35	)	73	(10	)	(10	)	54	(37	)	(37	)
Fasenra	949	35		34		12	n/m		n/m		603	25		203	72		70		131	33		32
Daliresp/Daxas	217	1		1		4	(9	)	(8	)	190	3		22	(14	)	(13	)	1	(10	)	(8	)
Bevespi	48	16		15		1	n/m		n/m		44	7		3	n/m		n/m		—	n/m		n/m
Breztri	28	n/m		n/m		14	n/m		n/m		5	n/m		—	n/m		n/m		9	n/m		n/m
Others	398	(15	)	(15	)	203	(15	)	(16	)	6	(12	)	176	(14	)	(15	)	13	(15	)	(7	)
Total Respiratory & Immunology	5,357	(1	)	n/m		1,599	(20	)	(18	)	1,941	17		1,171	6		5		646	n/m		1
Other:
Nexium	1,492	1		2		757	1		4		169	(22	)	71	12		10		495	9		8
Synagis	372	4		4		n/m	n/m		n/m		47	2		325	4		4		n/m	n/m		n/m
Flumist	295	n/m		n/m		1	n/m		n/m		70	n/m		219	n/m		n/m		5	n/m		n/m
Losec/Prilosec	183	(30	)	(30	)	152	(15	)	(14	)	6	(44	)	20	(59	)	(59	)	5	(78	)	(79	)
Seroquel XR/IR	117	(39	)	(37	)	55	11		14		17	(48	)	29	(67	)	(67	)	16	(19	)	(18	)
Others	128	(33	)	(34	)	6	(51	)	(44	)	55	(50	)	58	(7	)	(8	)	9	6		(5	)
Total Other	2,587	(1	)	n/m		971	(2	)	1		364	(17	)	722	8		7		530	5		3
Total Product Sales	25,890	10		11		8,679	6		10		8,638	12		5,059	16		15		3,514	6		6

3

	World					Emerging Markets					U.S.				Europe					Established ROW
2019	Sales $m	Actual %		CER %		Sales $m	Actual %		CER %		Sales $m		Actual %		Sales $m	Actual %		CER %		Sales $m	Actual %		CER %
Oncology:
Tagrisso	3,189	71		74		762	n/m		n/m		1,268		46		474	51		59		685	n/m		n/m
Imfinzi	1,469	n/m		n/m		30	n/m		n/m		1,041		85		179	n/m		n/m		219	n/m		n/m
Lynparza	1,198	85		89		133	n/m		n/m		626		81		287	51		59		152	n/m		n/m
Calquence	164	n/m		n/m		2	n/m		n/m		162		n/m		n/m	n/m		n/m		n/m	n/m		n/m
Faslodex	892	(13	)	(11	)	198	29		36		328		(39	)	229	3		9		137	19		17
Zoladex	813	8		13		492	20		28		7		(17	)	135	2		7		179	(11	)	(10	)
Iressa	423	(18	)	(15	)	286	n/m		4		17		(33	)	70	(36	)	(32	)	50	(49	)	(49	)
Arimidex	225	6		11		152	15		21		n/m		n/m		28	(8	)	(3	)	45	(9	)	(9	)
Casodex	200	n/m		3		127	13		19		n/m		(88	)	16	(20	)	(15	)	57	(15	)	(15	)
Others	94	(18	)	(17	)	29	(6	)	(3	)	n/m		n/m		5	(24	)	(19	)	60	(21	)	(22	)
Total Oncology	8,667	44		47		2,211	45		52		3,449		43		1,423	35		42		1,584	53		52
CVRM:
Farxiga	1,543	11		14		471	40		48		537		(9	)	373	18		25		162	9		10
Brilinta	1,581	20		23		462	42		49		710		21		351	1		7		58	(1	)	3
Bydureon	549	(6	)	(5	)	11	34		39		459		(3	)	66	(19	)	(14	)	13	(32	)	(28	)
Onglyza	527	(3	)	n/m		176	3		9		230		3		70	(22	)	(17	)	51	(14	)	(12	)
Byetta	110	(13	)	(11	)	12	47		60		68		(9	)	19	(35	)	(31	)	11	(24	)	(20	)
Other diabetes	52	33		35		1	n/m		n/m		40		18		9	88		n/m		2	23		33
Lokelma	14	n/m		n/m		n/m	n/m		n/m		13		n/m		1	n/m		n/m		n/m	n/m		n/m
Crestor	1,278	(11	)	(8	)	806	(4	)	n/m		104		(39	)	148	(27	)	(23	)	220	n/m		1
Seloken/Toprol-XL	760	7		12		686	7		13		37		(5	)	25	31		31		12	(11	)	(8	)
Atacand	221	(15	)	(11	)	160	2		7		12		(11	)	30	(57	)	(57	)	19	1		7
Others	271	(9	)	(6	)	193	(6	)	(3	)	(1	)	(91	)	59	(16	)	(12	)	20	(16	)	(16	)
Total CVRM	6,906	3		6		2,978	10		16		2,209		n/m		1,151	(6	)	(1	)	568	(2	)	n/m
Respiratory:
Symbicort	2,495	(3	)	n/m		547	11		17		829		(4	)	678	(12	)	(7	)	441	2		3
Pulmicort	1,466	14		18		1,190	20		24		110		(5	)	81	(10	)	(4	)	85	1		1
Fasenra	704	n/m		n/m		5	n/m		n/m		482		n/m		118	n/m		n/m		99	n/m		n/m
Daliresp/Daxas	215	14		15		4	(18	)	(13	)	184		19		26	(8	)	(3	)	1	32		35
Duaklir	77	(19	)	(15	)	1	44		49		3		n/m		71	(22	)	(17	)	2	(65	)	(64	)
Bevespi	42	26		26		n/m	n/m		n/m		42		25		n/m	n/m		n/m		n/m	n/m		n/m
Breztri	2	n/m		n/m		n/m	n/m		n/m		n/m		n/m		n/m	n/m		n/m		2	n/m		n/m
Others	390	(13	)	(9	)	240	62		70		3		(88	)	133	(38	)	(35	)	14	(74	)	(73	)
Total Respiratory	5,391	10		13		1,987	21		27		1,653		17		1,107	(10	)	(5	)	644	4		4
Other:
Nexium	1,483	(13	)	(11	)	748	8		14		218		(29	)	63	(73	)	(72	)	454	(4	)	(4	)
Synagis	358	(46	)	(46	)	n/m	(100	)	(100	)	46		(84	)	312	(17	)	(17	)	n/m	n/m		n/m
Losec/Prilosec	263	(3	)	1		179	11		17		10		43		49	(30	)	(26	)	25	(27	)	(26	)
Seroquel XR/IR	191	(47	)	(46	)	50	(58	)	(57	)	34		(69	)	88	(18	)	(14	)	19	(30	)	(30	)
Others	306	(23	)	(20	)	12	(77	)	(81	)	128		(4	)	157	(1	)	2		9	(84	)	(67	)
Total Other	2,601	(24	)	(21	)	989	(3	)	1		436		(48	)	669	(29	)	(28	)	507	(14	)	(12	)
Total Product Sales	23,565	12		15		8,165	18		24		7,747		13		4,350	(2	)	2		3,303	17		18

4

	World					Emerging Markets						U.S.				Europe					Established ROW
2018	Sales $m	Actual %		CER %		Sales $m		Actual %		CER %		Sales $m		Actual %		Sales $m	Actual %		CER %		Sales $m	Actual %		CER %
Oncology:
Tagrisso	1,860	95		93		347		n/m		n/m		869		n/m		314	68		61		330	45		43
Imfinzi	633	n/m		n/m		6		n/m		n/m		564		n/m		27	n/m		n/m		36	n/m		n/m
Lynparza	647	n/m		n/m		51		n/m		n/m		345		n/m		190	46		41		61	n/m		n/m
Calquence	62	n/m		n/m		n/m		n/m		n/m		62		n/m		n/m	n/m		n/m		n/m	n/m		n/m
Faslodex	1,028	9		9		154		34		41		537		9		221	(14	)	(19	)	116	49		46
Zoladex	752	2		2		409		16		18		8		(47	)	133	(6	)	(10	)	202	(11	)	(12	)
Iressa	518	(2	)	(4	)	286		14		12		26		(33	)	109	(3	)	(8	)	97	(23	)	(25	)
Arimidex	212	(2	)	(3	)	132		12		11		n/m		n/m		31	(9	)	(9	)	49	(16	)	(17	)
Casodex	201	(7	)	(8	)	113		5		2		1		n/m		20	(9	)	(9	)	67	(22	)	(23	)
Others	115	1		(1	)	30		29		30		n/m		n/m		8	20		20		77	(7	)	(8	)
Total Oncology	6,028	50		49		1,528		36		37		2,412		n/m		1,053	19		14		1,035	16		14
CVRM:
Farxiga	1,391	30		30		336		45		52		591		21		315	30		24		149	34		34
Brilinta	1,321	22		21		326		46		48		588		16		348	18		13		59	16		16
Bydureon	584	2		1		8		(11	)	(11	)	475		4		81	(8	)	(13	)	20	5		5
Onglyza	543	(11	)	(11	)	172		32		34		223		(30	)	89	(14	)	(18	)	59	4		4
Byetta	126	(28	)	(28	)	8		(33	)	(33	)	74		(35	)	29	(15	)	(15	)	15	(6	)	(6	)
Other diabetes	39	(26	)	(26	)	(1	)	n/m		n/m		34		(35	)	5	n/m		n/m		1	n/m		n/m
Lokelma	n/m	n/m		n/m		n/m		n/m		n/m		n/m		n/m		n/m	n/m		n/m		n/m	n/m		n/m
Crestor	1,433	(39	)	(40	)	841		7		7		170		(54	)	203	(70	)	(71	)	219	(60	)	(60	)
Seloken/Toprol-XL	712	2		4		641		8		10		39		5		19	(63	)	(63	)	13	n/m		n/m
Atacand	260	(13	)	(12	)	157		(12	)	(7	)	13		(32	)	70	(19	)	(20	)	20	18		18
Others	301	(11	)	(12	)	207		1		n/m		(1	)	n/m		71	(17	)	(23	)	24	(44	)	(44	)
Total CVRM	6,710	(8	)	(8	)	2,695		14		15		2,206		(7	)	1,230	(26	)	(29	)	579	(33	)	(34	)
Respiratory:
Symbicort	2,561	(9	)	(10	)	495		13		14		862		(22	)	773	(6	)	(10	)	431	(3	)	(4	)
Pulmicort	1,286	9		8		995		18		17		116		(26	)	90	(2	)	(8	)	85	(3	)	(5	)
Fasenra	297	n/m		n/m		1		n/m		n/m		218		n/m		32	n/m		n/m		46	n/m		n/m
Daliresp/ Daxas	189	(5	)	(5	)	5		25		25		155		(7	)	28	8		4		1	n/m		n/m
Duaklir	95	20		14		1		n/m		n/m		n/m		n/m		91	18		12		3	50		50
Bevespi	33	n/m		n/m		n/m		n/m		n/m		33		n/m		n/m	n/m		n/m		n/m	n/m		n/m
Breztri	n/m	n/m		n/m		n/m		n/m		n/m		n/m		n/m		n/m	n/m		n/m		n/m	n/m		n/m
Others	450	4		2		147		40		38		32		(55	)	215	6		3		56	n/m		n/m
Total Respiratory	4,911	4		3		1,644		18		18		1,416		(6	)	1,229	1		(4	)	622	5		4
Other:
Nexium	1,702	(13	)	(14	)	690		1		1		306		(39	)	235	(6	)	(11	)	471	(10	)	(11	)
Synagis	665	(3	)	(3	)	1		n/m		n/m		287		(9	)	377	2		2		n/m	n/m		n/m
Losec/Prilosec	272	n/m		(2	)	161		15		11		7		(36	)	70	(9	)	(12	)	34	(21	)	(21	)
Seroquel XR / IR	361	(29	)	(31	)	118		(22	)	(23	)	108		(44	)	107	(16	)	(20	)	28	(26	)	(26	)
Others	400	(46	)	(46	)	54		(82	)	(78	)	134		(9	)	158	(7	)	(14	)	54	(56	)	(57	)
Total Other	3,400	(18	)	(19	)	1,024		(19	)	(19	)	842		(28	)	947	(5	)	(8	)	587	(19	)	(20	)
Total Product Sales	21,049	4		4		6,891		12		13		6,876		11		4,459	(6	)	(10	)	2,823	(8	)	(9	)

All commentary in “—Geographical Review” relates to Product Sales. The market definitions used in the geographical areas review below are defined in the Glossary on page 280 of AstraZeneca’s “Annual Report and Form 20-F Information 2020” included as Exhibit 15.1 to this Form 20-F dated and submitted on February 16, 2021.

2020 in brief

Product Sales increased by 10% (CER: 11%) in 2020 to $25,890 million (2019: $23,565 million; 2018: $21,049 million) with the fourth quarter being the first for many years where the Product Sales exceeded $7,000 million.  The growth in Product Sales is primarily driven by solid performances of New Medicines in Emerging Markets.

Sales of New Medicines increased by 35% (CER: 36%) to $13,359 million (2019: $9,906 million; 2018: $6,244 million) including growth in Emerging Markets of 51% (CER: 57%) to $2,814 million (2019: $1,865 million; 2018: $1,067 million). New Medicines represented 52% of Total Product Sales (2019: 42%; 2018: 30%) globally with outstanding performances acros